On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Potential A-Share Listings by China’s Telecom Giants Won’t Phase Partnership with FingerMotion Inc. (FNGR)

  • FingerMotion Inc.’s proprietary PigeonHole Integration System works in tandem with the three major Chinese telecom giants, providing a large potential for growth and customer reach, especially since the market is predicted to go unchanged despite the uncertainty of economic conditions brought on by the pandemic
  • China Mobile is looking at potential A-share listings, whereas China Telecom has already announced the intention of listing with the Shanghai Stock Exchange with the issuance of 12 billion shares, with profits set to help fund the 5G industrial Internet project
  • Using the data collected from these telecom giants, FingerMotion will be able to fine-tune its current offering while developing other products

FingerMotion (OTCQX: FNGR) is a technology company, constantly evolving its core competencies in mobile payment and recharge platform solutions for mainland China. FingerMotion is positioned to capitalize on the telecom market growth and opportunities, as well as its partnership with the country’s telecommunications giants, through the company’s proprietary platform and technology. It is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers that can be resold to consumers.

One of China’s top mobile providers, China Mobile, is currently looking into the possibility of an A-share listing. Another one of China’s state-owned carriers, China Telecom, has already announced plans to list on the Shanghai Stock Exchange (“SSE”). The plan proposed by China Telecom will be to issue as many as 12 billion shares on the mainland China exchange – pricing is currently unknown, but it could come at a large premium. China Telecom plans to use the listing proceeds to construct a 5G industrial Internet project, boosting its cloud network. The Shanghai listing plan is currently waiting for approval by the Chinese Securities Regulatory Commission.

FingerMotion’s telecom products and services include a universal exchange platform, which has been named “PigeonHole Integration System (‘PIS’),” offering seamless integration between telecom operators and online stores.

PIS offers consumers top-up and recharge services, data plans, mobile phones, loyalty points redemption, and subscription plans. All transactions are reliable and secure, featuring real-time reconciliation and simple integration for partners with efficient settlements.

According to Research and Markets China Telecoms Report – 2020-2025, the Chinese telecommunications industry is expected to remain steady even with the political uncertainties and uncertain economic outlooks due to the COVID-19 pandemic. The report stated that the growing mobile phone penetration and high-fixed broadband among households would fuel the growth over the next five years (https://ibn.fm/lymhT).

FingerMotion is currently working to strengthen the existing and strategic partnerships it has with the Chinese telecommunication giants. Through the partnerships, the company will gain access to comprehensive and unbiased telco data on a real-time, unimpeded basis while covering a massive population. FingerMotion will then transform and integrate with its own proprietary collection for more effective and efficient capitalization and delivery using this data.

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom https://ibn.fm/FNGR

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.